HLB Therapeutics Co.,Ltd.
115450
Pozycja w akcjach
#18702
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Cena akcji
$2.01
Kapitalizacja rynkowa
$189.24M
Zmiana (1 dzień)
7.15%
Zmiana (1 rok)
-1.89%
Kraj
KR
Handel HLB Therapeutics Co.,Ltd. (115450)
Kategoria
Healthcare
Zyski dla HLB Therapeutics Co.,Ltd. (115450)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych HLB Therapeutics Co.,Ltd., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy HLB Therapeutics Co.,Ltd. od 2026 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
